Rising numbers of individuals receiving psoriasis biologics achieve clear/nearly clear skin (disease control). Trial data indicate some maintain control with lower doses, especially those with higher serum drug concentrations. This indicates potential for Model-Informed Precision Dosing (MIPD), an advanced therapeutic drug monitoring technique, in guiding dose minimisation. We developed, validated, and user-tested a precision dosing dashboard. We applied a MIPD approach leveraging Bayesian estimation to predict individual pharmacokinetic (PK) parameters for personalised dosing recommendations. A PK model of the exemplar biologic risankizumab, derived from phase I-III psoriasis trial data (13123 observations/1899 patients), was externally validated using real-world UK psoriasis data. The Bayesian model (posterior prediction: mean absolute error 0.89 mg/L
mean percentage error 19.55%
root mean square error 1.24 mg/L
R